From Financial Modeling Prep: 2025-06-04 11:00:00

Atai Life Sciences N.V. (NASDAQ:ATAI) focuses on developing treatments for mental health disorders, competing with peers like COMPASS Pathways and Mind Medicine. Atai’s ROIC is -55.24%, below its WACC of 11.14%, indicating capital inefficiencies. COMPASS and Mind Medicine face similar challenges with negative ROICs against their respective WACCs. Seelos Therapeutics stands out with a positive ROIC of 95.54% and a strong ROIC to WACC ratio of 17.93, showing efficient capital utilization and growth potential.



Read more at Financial Modeling Prep:: Atai Life Sciences N.V. (NASDAQ:ATAI) Financial Pe…